Scarica l'app Stockscreener
38.40
1.56%
0.59
Pre-mercato:
38.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyInvestor Friendly Risk Reward - beatles.ru
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Meds partners with AI specialist Iambic - The Pharma Letter
Revolution Medicines partners with Iambic for AI-driven drug discovery By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. and Iambic Therapeutics Announce Technology and Research Collaboration Using Iambic's Ai Discovery Tools to Pursue New Drug Candidates - MarketScreener
Revolution Medicines, Iambic Therapeutics Form AI-Powered Drug Discovery Partnership - MarketScreener
Revolution Medicines partners with Iambic for AI-driven drug discovery - Investing.com
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milesto - 富途牛牛
Revolution Medicines and Iambic Therapeutics Announce Collaboration to Explore Novel Drug Candidates Using Advanced AI Models - Quiver Quantitative
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates - The Manila Times
Revolution Medicines and Iambic Announce Technology and - GlobeNewswire
Revolution Medicines Taps Iambic's AI Platform in $25M Deal to Accelerate Cancer Drug Discovery - Stock Titan
16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey
Revolution Medicines’ SWOT analysis: stock’s potential in cancer therapies By Investing.com - Investing.com South Africa
Revolution Medicines’ SWOT analysis: stock’s potential in cancer therapies - Investing.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Revolution Medicines Insider Ups Holding During Year - simplywall.st
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - Yahoo Finance
Strategic Collaboration and Promising Trial Results Drive Buy Rating for Revolution Medicines - TipRanks
Revolution Medicines' Royalty Pharma Deal: A Strategic Masterstroke for Oncology Dominance - AInvest
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Index - MarketScreener
Tango Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines dips 5%, gets $2B flexible funding - MSN
Revolution Medicines partners Royalty Pharma on $2bn funding - Pharmaceutical Technology
Latham & Watkins Advises Revolution Medicines on US$2 Billion Growth Financing With Royalty Pharma - Latham & Watkins LLP
Revmed goes global with $2B in capital for RAS(ON) inhibitors - BioWorld MedTech
Revolution Medicines' Q2 Earnings Signal Clinical Breakthrough: A Catalyst for Pancreatic Cancer Therapy and Shareholder Value - AInvest
How big data and big deals may lead comebacks for Bay Area biotechsSan Francisco Business Times - The Business Journals
FDA grants breakthrough therapy designation to Revolution Medicines' drug By Investing.com - Investing.com Canada
This Revolution Medicines Insider Increased Their Holding In The Last Year - Yahoo Finance
Revolution Medicines: Pioneering RAS-Targeted Oncology with Clinical Momentum and Financial Strength - AInvest
Revolution Medicines director Weber resigns ahead of annual meeting - Investing.com
Revolution Medicines COO Horn sells $139k in stock - Investing.com
Revolution Medicines COO Horn sells $139k in stock By Investing.com - Investing.com UK
(RVMD) Proactive Strategies - news.stocktradersdaily.com
(RVMD) Investment Analysis - news.stocktradersdaily.com
rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Stellantis Lead - Barron's
Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance
Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace
Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus
When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com
Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus
Revolution Medicines begins phase 3 trial for lung cancer drug - Investing.com
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks
Revolutionary Cancer Drug Enters Phase 3 Trial, Targeting 30% of Lung Cancer Patients Without Current Options - Stock Titan
Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance
Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News
3.40%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):